A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib

Leukemia

Volumn 19, Issue 11, 2005, Pages 1859-1862

  Crossman, L C ^a,b   O'Hare, T ^a   Lange, T ^c   Willis, S G ^a   Stoffregen, E P ^a   Corbin, A S ^a   O'Brien, S G ^b   Heinrich, M C ^a,d   Druker, B J ^a,d   Middleton, P G ^b   Deininger, M W N ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

ABL; CML; Dasatinib; Imatinib; Polymorphism

Indexed keywords

ABELSON KINASE; ANTINEOPLASTIC AGENT; ARGININE; BCR ABL PROTEIN; DASATINIB; IMATINIB; LYSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; AUTOPHOSPHORYLATION; BIOASSAY; CELL ASSAY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; FEMALE; GENE FREQUENCY; GENETIC SCREENING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; RESTRICTION MAPPING; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; WILD TYPE;

EID: 27644596456     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403935     Document Type: Article

References (21)

1. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
2. Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Muller C et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5: 55-60.
3. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
4. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 2002; 359: 487-491.
5. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
6. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-2653.
7. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-283.
8. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol 2005; 23: 4100-4109.
9. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004; 11: 35-43.
10. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691-3698.
11. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5: 874-879.
12. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002; 62: 7149-7153.
13. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392-8396.
14. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611-4614.
15. Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002; 277: 32214-32219.
16. O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: Implications for CML. Blood 2004; 104: 2532-2539.
17. Melo JV, Yan XH, Diamond J, Goldman JM. Lack of imprinting of the ABL gene. Nat Genet 1994; 8: 318-319.
18. Irving JA, O'Brien S, Lennard AL, Minto L, Lin F, Hall AG. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to imatinib. Clin Chem 2004; 50: 1233-1237.
19. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/ imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831-843.
20. Fainstein E, Einat M, Gokkel E, Marcelle C, Croce CM, Gale RP et al. Nucleotide sequence analysis of human abl and bcr-abl cDNAs. Oncogene 1989; 4: 1477-1481.
21. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.